Globus Medical shares traded lower today as the market digested a new round of earnings-estimate tightening heading into the company’s next quarterly report. The latest catalyst is a FY2026 EPS estimate trim from Zacks, which lowered its projection to $4.40 from $4.42 in a research update dated April 23, keeping investors focused on whether post-merger integration and margin cadence can keep pace with expectations. (marketbeat.com)

The timing is notable: Globus Medical has scheduled its first-quarter 2026 results for May 7, putting the stock in a setup where even small changes in forward profit expectations can drive short-term repositioning. With the next earnings event close, traders often de-risk on incremental negative estimate revisions even when the company’s longer-term growth narrative remains intact. (api.finexus.net)

Earlier in 2026, the company pointed to strong momentum and issued full-year 2026 guidance calling for revenue of $3.18 billion to $3.22 billion and non-GAAP diluted EPS of $4.30 to $4.40, setting a high bar for execution. Today’s pullback suggests the market is re-checking how much upside is left versus what’s already priced in after the strong 2025 finish and optimism around integration benefits. (globenewswire.com)